Progress in Collaborative Drug Discovery Research with Four Pharmaceutical Companies
First written in FY2023. 3 of 9 entries say "Advanced", first in FY2024-H1. Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Other".
- FY2026-H1Joint Research Agreement ConcludedAnnual report
「The joint research with Takeda Pharmaceutical Company Limited had produced certain results, but following discussions and consideration by both companies, it ended in April 2026.」
While research with the existing 4 companies progressed, the joint research with Takeda Pharmaceutical Company Limited ended in April 2026. - FY2025AdvancedAnnual report
「The most advanced of the 4 projects is currently in the latter half of the “hit-to-lead” stage, specifically the lead-compound creation stage.」
The company continues joint drug-discovery research with 4 companies, and the leading project has advanced to the lead-compound creation stage in the latter half of hit-to-lead. - FY2025-H1AdvancedAnnual report
「In the platform business, or mRNA-targeted small-molecule drug-discovery business, joint drug-discovery research with each partner progressed smoothly. In the joint research with Shionogi & Co., Ltd., we successfully obtained a compound leading to the acquisition of a lead compound and achieved a milestone. In the joint research with RaQualia Pharma Inc. targeting the creation of cancer therapeutics, we expanded the scope of target-gene research, conducted multiple screenings against multiple genes by combining the expertise of both companies, and obtained multiple small-molecule compounds that could serve as starting points for drug discovery.」
For the existing 4 joint drug-discovery research projects, Shionogi & Co., Ltd. obtained a compound leading to a lead compound and achieved a milestone. RaQualia Pharma Inc. expanded the scope of target-gene research, conducted screenings against multiple genes and obtained multiple small-molecule compounds. - FY2024-H1AdvancedAnnual report
「During the interim accounting period, joint drug-discovery research with each partner in the mRNA-targeted small-molecule drug-discovery business progressed smoothly, producing results including the designation of hit compounds.」
The company moved from reporting continuation and progress of joint research with 4 companies to reporting concrete results, including the designation of hit compounds. - FY2024-Q1RestatedAnnual report
「Our mRNA-targeted small-molecule drug-discovery business continues joint drug-discovery research with Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited, hereinafter collectively referred to as “partners.” During the cumulative first-quarter period, joint drug-discovery research with the 4 partners progressed. We will work steadily to conduct joint drug-discovery research with each partner toward achievement of the next research milestone.」
The company reports the continuation and progress of joint drug-discovery research with 4 companies, but does not indicate achievement of a specific milestone; the substantive development is therefore limited to reconfirmation. - FY2023First statedAnnual report
「Projects are currently progressing with 4 joint drug-discovery research partners: Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited.」
As of the end of December 2023, projects were underway with Toray Industries, Shionogi & Co., RaQualia Pharma and Takeda Pharmaceutical Company. The most advanced project was reported to be at the hit-compound validation stage.